Fractyl Health, Inc.
$0.58
▼
-1.89%
2026-04-21 07:13:01
fractyl.com
NGM: GUTS
Explore Fractyl Health, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$90.33 M
Current Price
$0.58
52W High / Low
$3.03 / $0.38
Stock P/E
—
Book Value
$0.06
Dividend Yield
—
ROCE
-93.93%
ROE
-7.44%
Face Value
—
EPS
$-1.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
100
Beta
1.19
Debt / Equity
651.79
Current Ratio
4.78
Quick Ratio
4.78
Forward P/E
-0.81
Price / Sales
—
Enterprise Value
$53.08 M
EV / EBITDA
-0.56
EV / Revenue
—
Rating
None
Target Price
$5.24
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Immix Biopharma, Inc. | $10.09 | — | $548.68 M | — | -31.62% | -55% | $11.61 / $1.57 | $1.77 |
| 2. | PMV Pharmaceuticals, Inc. | $1.43 | — | $73.59 M | — | -81.99% | -55.37% | $1.88 / $0.81 | $1.96 |
| 3. | Precigen, Inc. | $4.11 | — | $1.45 B | — | -90.19% | -5.72% | $5.46 / $1.23 | $0.06 |
| 4. | XOMA Royalty Corporation | $40 | 14.61 | $463.38 M | 1.18% | 4.79% | 34.12% | $40.74 / $20.59 | $7.07 |
| 5. | Capricor Therapeutics, Inc. | $34.21 | — | $2.04 B | — | -33.78% | -46.56% | $40.37 / $4.3 | $5.33 |
| 6. | BioRestorative Therapies, Inc. | $0.26 | — | $6.72 M | — | -4386.1% | -3.2% | $2.04 / $0.19 | $0.04 |
| 7. | NeuroSense Therapeutics Ltd. | $0.71 | — | $25.1 M | — | -383.35% | -21.75% | $2.6 / $0.63 | $-0.05 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -23.28 M | -22.69 M | -26.08 M | -24.76 M | -25.21 M |
| Net Profit | -43.73 M | -45.6 M | -27.89 M | -23.73 M | -24.97 M |
| EPS in Rs | -0.28 | -0.29 | -0.18 | -0.15 | -0.16 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0.09 M | 0.12 M | 0 M |
| Operating Profit | -96.82 M | -93.53 M | -50.84 M | -49.38 M |
| Net Profit | -140.95 M | -68.69 M | -77.09 M | -46.45 M |
| EPS in Rs | -0.89 | -0.43 | -0.49 | -0.29 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 121.4 M | 108.08 M | 76.21 M | 60.96 M |
| Total Liabilities | 111.94 M | 79.65 M | 401.27 M | 313.27 M |
| Equity | 9.46 M | 28.42 M | -325.06 M | -252.32 M |
| Current Assets | 87.58 M | 71.76 M | 35.65 M | 51.63 M |
| Current Liabilities | 18.33 M | 19.77 M | 11.19 M | 7.31 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -90.33 M | -65.52 M | -42.82 M | -46.24 M |
| Investing CF | -0.56 M | -1.76 M | -0.36 M | -0.06 M |
| Financing CF | 104.96 M | 101.23 M | 27.44 M | 4.35 M |
| Free CF | -90.89 M | -67.29 M | -43.18 M | -46.3 M |
| Capex | -0.56 M | -1.76 M | -0.36 M | -0.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -22.5% | — | — | — |
| Earnings Growth % | 10.89% | -65.95% | — | — |
| Profit Margin % | -73864.52% | -64242.5% | — | — |
| Operating Margin % | -100570.97% | -42363.33% | — | — |
| Gross Margin % | 46.24% | 35.83% | — | — |
| EBITDA Margin % | -99843.01% | -42125% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.